Table 3.
Summary of the endpoints stratified for each trial.
| Endpoints | RENAL-AF [19] |
AXADIA AFNET 8 [23] |
VALKYRIE [22] |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Intervention n = 82 | Control n = 72 | ARR | Intervention n = 48 | Control n = 49 | ARR | Intervention n = 88 | Control n = 44 | ARR | |
| All-cause death, n (%) | 21 (25.6) | 13 (18.1) | 7.5 | 9 (18.7) | 12 (24.5) | -5.7 | 57 (64.7) | 32 (72.7) | -8.0 |
| Total bleedings, n (%) | 21 (25.6) | 16 (22.2) | 3.4 | 15 (31.2) | 15 (30.6) | 0.6 | 43 (48.8) | 24 (54.5) | -5.6 |
| Lift-threatening or major bleedings, n (%) | 9 (10.9) | 7 (9.7) | 1.2 | 5 (10.4) | 6 (12.2) | -1.8 | 17 (19.3) | 17 (38.6) | -19.3 |
| Thromboembolic events or stroke, n (%) | 1 (1.2) | 2 (2.7) | -1.5 | 0 (0) | 1 (2.0) | 2.0 | 6 (6.8) | 7 (15.9) | -9.1 |
ARR, absolute risk reduction.
Table 3 presents potential bias of all in the present meta-analysis included trials as judged by the authors and in accordance with the revised Cochrane’s Collaboration risk of bias assessment tool.